Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus

Ivana Dostálová, Denisa Haluzíková, Martin Haluzík

. 2009 ; 58 (1) : 1-7.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07528755

Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic actions of FGF21 are adipose tissue, liver and pancreas. Experimental studies have shown marked improvements in diabetes compensation and dyslipidemia after FGF21 administration in diabetic mice and primates. Positive metabolic actions of FGF21 without the presence of apparent side effects make this factor a hot candidate to treat type 2 diabetes and accompanying metabolic diseases. The aim of this review is to summarize the current knowledge about the metabolic effects of FGF21 including some preliminary data on changes of its levels in humans with a special emphasis on its therapeutic potential in type 2 diabetes mellitus.

Citace poskytuje Crossref.org

Bibliografie atd.

Lit.: 43

000      
00000naa 2200000 a 4500
001      
bmc07528755
003      
CZ-PrNML
005      
20111210145616.0
008      
090915s2009 xr e eng||
009      
AR
024    7_
$a 10.33549/physiolres.931610 $2 doi
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Dostálová, Ivana $7 xx0075775
245    10
$a Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus / $c Ivana Dostálová, Denisa Haluzíková, Martin Haluzík
314    __
$a Third Department of Medicine, First Faculty of Medicine, Charles University, Prague
504    __
$a Lit.: 43
520    9_
$a Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic actions of FGF21 are adipose tissue, liver and pancreas. Experimental studies have shown marked improvements in diabetes compensation and dyslipidemia after FGF21 administration in diabetic mice and primates. Positive metabolic actions of FGF21 without the presence of apparent side effects make this factor a hot candidate to treat type 2 diabetes and accompanying metabolic diseases. The aim of this review is to summarize the current knowledge about the metabolic effects of FGF21 including some preliminary data on changes of its levels in humans with a special emphasis on its therapeutic potential in type 2 diabetes mellitus.
650    _2
$a financování organizované $7 D005381
650    _2
$a zvířata $7 D000818
650    _2
$a látky proti obezitě $x škodlivé účinky $x terapeutické užití $7 D019440
650    _2
$a diabetes mellitus 2. typu $x farmakoterapie $x metabolismus $7 D003924
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a energetický metabolismus $x účinky léků $7 D004734
650    _2
$a fibroblastové růstové faktory $x metabolismus $x terapeutické užití $x účinky léků $7 D005346
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x škodlivé účinky $x terapeutické užití $7 D007004
650    _2
$a obezita $x farmakoterapie $x metabolismus $7 D009765
650    _2
$a signální transdukce $x účinky léků $7 D015398
700    1_
$a Haluzíková, Denisa, $d 1970- $7 jo2003163140
700    1_
$a Haluzík, Martin, $d 1970- $7 xx0000707
773    0_
$w MED00003824 $t Physiological research $g Roč. 58, č. 1 (2009), s. 1-7 $x 0862-8408
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/58/58_1.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 9
990    __
$a 20090910142741 $b ABA008
991    __
$a 20090915111128 $b ABA008
999    __
$a ok $b bmc $g 679802 $s 539778
BAS    __
$a 3
BMC    __
$a 2009 $b 58 $c 1 $d 1-7 $i 0862-8408 $m Physiological research $x MED00003824
LZP    __
$a 2009-31/mkme

Najít záznam

Citační ukazatele

Možnosti archivace